Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Pharma Technology Focus: Taming big pharma
  2. FDA approves Grifols’ Xembify for immunodeficiencies
  3. Pharma Technology Focus: digitising the API supply chain
  4. Pharma Technology Focus: is a memory loss drug on the horizon?

Latest Content

Are M&As the Key to Securing Growth in the Orphan Drugs Sector?

The orphan drug market can be an alluringly lucrative sector. Most big pharma corporations inherit these specialty business units through mergers and acquisitions (M&As). Yet it is not a viable sector for all pharmaceutical companies as it requires specialist capabilities.

2019 Temperature Control Catalogue

Huber’s new temperature control catalogue 2019 has been completely revised and highlights a wide range of equipment for in laboratory, mini plant and production, including chillers and high dynamic temperature control systems, as well as classical baths and circulators for working temperatures from -125°C to +425 °C.

FDA approves Grifols’ Xembify for immunodeficiencies

Spanish plasma-derived medicine specialist Grifols has announced that the US Food and Drug Administration (FDA) has approved its Xembify (immune globulin subcutaneous, human- klhw) for patients over two years old with primary immunodeficiencies.

Annex 1 and Continuing Monitoring Solutions

The upcoming revision and the current draft of Annex 1 indicate that continuous monitoring is a requirement in cleanrooms. The question is how to do that effectively and in an acceptable manner.

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Close
Close
Close

Go Top